A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined 39.5% over the past four weeks. However, given the fact that it is now in ...

Cassava Sciences, Inc.’s SAVA share price has surged by 5.51%, which has investors questioning if this is right time to sell.

March 25 (Reuters) - Cassava Sciences (SAVA.O), opens new tab said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory scrutiny, failed in a second late-stage ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental ...

Write to [email protected] Cassava Sciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Cassava Sciences' simufilam failed to meet co-primary endpoints in the Phase 3 REFOCUS-ALZ trial for mild-to-moderate Alzheimer's disease. Cassava will discontinue Alzheimer's drug development ...

Simufilam continued to demonstrate an overall favorable safety profile. About REFOCUS-ALZ Cassava Sciences NewsMORE Related Stocks ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. Months after seeing one phase 3 trial fail, the biotech is planning to stop development altogether after chalking up another ...

SAVA has a new potential indication for simufilam, the treatment of seizures related to tuberous sclerosis complex, although the company is not yet running a clinical trial here. SAVA isn't done ...

Cassava Sciences, Inc. (SAVA) (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for central nervous ...

AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company ...